Viracta Therapeutics (VIRX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

VIRX Stock Forecast


Viracta Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 3900.00% upside from VIRX’s last price of $0.20) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

VIRX Price Target


The average price target for Viracta Therapeutics (VIRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 3900.00% upside from VIRX's last price of $0.20.

VIRX Analyst Ratings


Buy

According to 2 Wall Street analysts, Viracta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VIRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Viracta Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2022-RBC Capital$8.00$3.33140.24%3900.00%
Row per page
Go to

The latest Viracta Therapeutics stock forecast, released on Nov 11, 2022 by RBC Capital company, set a price target of $8.00, which represents a 140.24% increase from the stock price at the time of the forecast ($3.33), and a 3900.00% increase from VIRX last price ($0.20).

Viracta Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.20$0.20$0.20
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Viracta Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viracta Therapeutics's last price of $0.20. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 23, 2024OppenheimerOutperformOutperformHold
Nov 11, 2022RBC CapitalOutperformOutperformHold
Row per page
Go to

Viracta Therapeutics's last stock rating was published by Oppenheimer on May 23, 2024. The company gave VIRX a "Outperform" rating, the same as its previous rate.

Viracta Therapeutics Financial Forecast


Viracta Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 21Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue---------$120.00K$2.07M---
Avg Forecast-------$4.50M$375.00K$375.00K$625.00K$200.00K$200.00K$300.00K
High Forecast-------$4.50M$375.00K$375.00K$625.00K$200.00K$200.00K$300.00K
Low Forecast-------$4.50M$375.00K$375.00K$625.00K$200.00K$200.00K$300.00K
# Analysts-------1111111
Surprise %---------0.32%3.32%---

Viracta Therapeutics's average Quarter revenue forecast for Jun 20 based on 1 analysts is $375.00K, with a low forecast of $375.00K, and a high forecast of $375.00K. VIRX's average Quarter revenue forecast represents a 212.50% increase compared to the company's last Quarter revenue of $120.00K (Mar 20).

Viracta Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 21Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts-------1111111
EBITDA-------$-79.11M$-6.33M$-5.81M$-5.29M$-5.87M$-6.13M$-5.60M
Avg Forecast-------$900.00K$75.00K$75.00K$125.00K$40.00K$40.00K$60.00K
High Forecast-------$900.00K$75.00K$75.00K$125.00K$40.00K$40.00K$60.00K
Low Forecast-------$900.00K$75.00K$75.00K$125.00K$40.00K$40.00K$60.00K
Surprise %--------87.90%-84.33%-77.49%-42.34%-146.73%-153.20%-93.28%

undefined analysts predict VIRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viracta Therapeutics's previous annual EBITDA (undefined) of $NaN.

Viracta Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 21Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts-------1111111
Net Income-------$-79.62M$-6.39M$-7.09M$-5.36M$-6.01M$-6.35M$-6.12M
Avg Forecast$-6.70M$-6.70M$-8.67M$-8.28M$-7.49M$-10.51M$-14.45M$-1.63B$-75.85M$-96.54M$-99.99M$-117.23M$-137.92M$-237.91M
High Forecast$-6.70M$-6.70M$-8.67M$-8.28M$-7.49M$-10.51M$-14.45M$-1.30B$-75.85M$-96.54M$-99.99M$-117.23M$-137.92M$-237.91M
Low Forecast$-6.70M$-6.70M$-8.67M$-8.28M$-7.49M$-10.51M$-14.45M$-1.96B$-75.85M$-96.54M$-99.99M$-117.23M$-137.92M$-237.91M
Surprise %-------0.05%0.08%0.07%0.05%0.05%0.05%0.03%

Viracta Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VIRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Viracta Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 21Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts-------1111111
SG&A-------$3.84M$2.06M$2.23M$2.48M$2.51M$2.52M$2.44M
Avg Forecast-------$47.13M$3.93M$3.93M$6.55M$2.09M$2.09M$3.14M
High Forecast-------$47.13M$3.93M$3.93M$6.55M$2.09M$2.09M$3.14M
Low Forecast-------$47.13M$3.93M$3.93M$6.55M$2.09M$2.09M$3.14M
Surprise %-------0.08%0.53%0.57%0.38%1.20%1.20%0.78%

Viracta Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VIRX last annual SG&A of $3.84M (Mar 21).

Viracta Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 21Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts-------1111111
EPS-------$-5.25$-0.17$-0.19$-0.48$-0.57$-0.88$-1.03
Avg Forecast$-0.17$-0.17$-0.22$-0.21$-0.19$-0.27$-0.37$0.02$-1.93$-2.45$-2.54$-2.98$-3.50$-6.04
High Forecast$-0.17$-0.17$-0.22$-0.21$-0.19$-0.27$-0.37$0.02$-1.93$-2.45$-2.54$-2.98$-3.50$-6.04
Low Forecast$-0.17$-0.17$-0.22$-0.21$-0.19$-0.27$-0.37$0.02$-1.93$-2.45$-2.54$-2.98$-3.50$-6.04
Surprise %--------225.00%0.09%0.08%0.19%0.19%0.25%0.17%

According to undefined Wall Street analysts, Viracta Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VIRX previous annual EPS of $NaN (undefined).

Viracta Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SQZSQZ Bio$0.44$400.0090809.09%Buy
VIRXViracta Therapeutics$0.20$8.003900.00%Buy
ALXOALX Oncology$1.49$24.501544.30%Buy
VINCVincerx Pharma$0.36$3.00733.33%Buy
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
CABACabaletta Bio$4.00$16.33308.25%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
TRVITrevi Therapeutics$3.04$8.00163.16%Buy
BMEABiomea Fusion$8.84$22.75157.35%Buy
EYPTEyePoint Pharmaceuticals$11.70$30.00156.41%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
BCYCBicycle Therapeutics$23.46$54.40131.88%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
LYRALyra Therapeutics$0.26$0.5092.31%Hold
MREOMereo BioPharma Group$4.01$6.7568.33%Buy
LPTXLeap Therapeutics$3.67$5.5049.86%Buy
IGMSIGM Biosciences$15.69$20.3329.57%Buy

VIRX Forecast FAQ


Yes, according to 2 Wall Street analysts, Viracta Therapeutics (VIRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VIRX's total ratings.

Viracta Therapeutics (VIRX) average price target is $8 with a range of $8 to $8, implying a 3900.00% from its last price of $0.2. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for VIRX stock, the company can go up by 3900.00% (from the last price of $0.2 to the average price target of $8), up by 3900.00% based on the highest stock price target, and up by 3900.00% based on the lowest stock price target.

VIRX's average twelve months analyst stock price target of $8 supports the claim that Viracta Therapeutics can reach $0 in the near future.

Viracta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.444M (high $-32.444M, low $-32.444M), average SG&A $0 (high $0, low $0), and average EPS is $-0.823 (high $-0.823, low $-0.823). VIRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.342M (high $-30.342M, low $-30.342M), average SG&A $0 (high $0, low $0), and average EPS is $-0.77 (high $-0.77, low $-0.77).

Based on Viracta Therapeutics's last annual report (Dec 2019), the company's revenue was $2.07M, beating the average analysts forecast of $1.32M by 56.45%. Apple's EBITDA was $-22.886M, missing the average prediction of $265K by -8736.36%. The company's net income was $-23.844M, missing the average estimation of $-593M by -95.98%. Apple's SG&A was $9.95M, missing the average forecast of $13.88M by -28.31%. Lastly, the company's EPS was $-2.74, missing the average prediction of $-15.05 by -81.79%. In terms of the last quarterly report (Mar 2020), Viracta Therapeutics's revenue was $120K, missing the average analysts' forecast of $375K by -68.00%. The company's EBITDA was $-5.812M, missing the average prediction of $75K by -7849.44%. Viracta Therapeutics's net income was $-7.093M, missing the average estimation of $-96.542M by -92.65%. The company's SG&A was $2.23M, missing the average forecast of $3.93M by -43.27%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-2.45 by -92.24%